Phase II trial of vorinostat in advanced melanoma von Haas, N. B., Quirt, I., Hotte, S., McWhirter, E., Polintan, R., Litwin, S., Adams, P. D., McBryan, T., Wang, L., Martin, L. P., vonMehren, M., Alpaugh, R. K., Zweibel, J., Oza, A.

Volltext

Pembrolizumab for advanced prostate adenocarcinoma: findings of the KEYNOTE-028 study von Hansen, A.R., Massard, C., Ott, P.A., Haas, N.B., Lopez, J.S., Ejadi, S., Wallmark, J.M., Keam, B., Delord, J.-P., Aggarwal, R., Gould, M., Yang, P., Keefe, S.M., Piha-Paul, S.A.

Volltext

Validation of a new prognostic model to easily predict outcome in renal cell carcinoma: the GRANT score applied to the ASSURE trial population von Buti, S., Puligandla, M., Bersanelli, M., DiPaola, R.S., Manola, J., Taguchi, S., Haas, N.B.

Volltext

A randomized phase II trial of CRLX101 in combination with bevacizumab versus standard of care in patients with advanced renal cell carcinoma von Voss, M.H., Hussain, A., Vogelzang, N., Lee, J.L., Keam, B., Rha, S.Y., Vaishampayan, U., Harris, W.B., Richey, S., Randall, J.M., Shaffer, D., Cohn, A., Crowell, T., Li, J., Senderowicz, A., Stone, E., Figlin, R., Motzer, R.J., Haas, N.B., Hutson, T.

Volltext

Efficacy of the nanoparticle–drug conjugate CRLX101 in combination with bevacizumab in metastatic renal cell carcinoma: results of an investigator-initiated phase I–IIa clinical tr... von Keefe, S.M., Hoffman-Censits, J., Cohen, R.B., Mamtani, R., Heitjan, D., Eliasof, S., Nixon, A., Turnbull, B., Garmey, E.G., Gunnarsson, O., Waliki, M., Ciconte, J., Jayaraman, L., Senderowicz, A., Tellez, A.B., Hennessy, M., Piscitelli, A., Vaughn, D., Smith, A., Haas, N.B.

Volltext

Validation of a new prognostic model to easily predict outcome in renal cell carcinoma: the GRANT score applied to the ASSURE trial population von Buti, S., Puligandla, M., Bersanelli, M., DiPaola, R.S., Manola, J., Taguchi, S., Haas, N.B.

Volltext

In vitro hypoxia-conditioned colon cancer cell lines derived from HCT116 and HT29 exhibit altered apoptosis susceptibility and a more angiogenic profile in vivo von Yao, K, Gietema, J A, Shida, S, Selvakumaran, M, Fonrose, X, Haas, N B, Testa, J, O'Dwyer, P J

Volltext

Adjuvant Pembrolizumab after Nephrectomy in Renal-Cell Carcinoma von Choueiri, Toni K, Tomczak, Piotr, Park, Se Hoon, Venugopal, Balaji, Ferguson, Thomas, Chang, Yen-Hwa, Hajek, Jaroslav, Symeonides, Stefan N, Lee, Jae Lyun, Sarwar, Naveed, Thiery-Vuillemin, Antoine, Gross-Goupil, Marine, Mahave, Mauricio, Haas, Naomi B, Sawrycki, Piotr, Gurney, Howard, Chevreau, Christine, Melichar, Bohuslav, Kopyltsov, Evgeniy, Alva, Ajjai, Burke, John M, Doshi, Gurjyot, Topart, Delphine, Oudard, Stephane, Hammers, Hans, Kitamura, Hiroshi, Bedke, Jens, Perini, Rodolfo F, Zhang, Pingye, Imai, Kentaro, Willemann-Rogerio, Jaqueline, Quinn, David I, Powles, Thomas

Volltext

Chicken Repeat 1 Elements Contain a pol-Like Open Reading Frame and Belong to the Non-Long Terminal Repeat Class of Retrotransposons von John B. E. Burch, Davis, Dorene L., Haas, Naomi B.

Volltext

Overall Survival with Adjuvant Pembrolizumab in Renal-Cell Carcinoma von Choueiri, Toni K., Tomczak, Piotr, Park, Se Hoon, Venugopal, Balaji, Ferguson, Tom, Symeonides, Stefan N., Hajek, Jaroslav, Chang, Yen-Hwa, Lee, Jae-Lyun, Sarwar, Naveed, Haas, Naomi B., Gurney, Howard, Sawrycki, Piotr, Mahave, Mauricio, Gross-Goupil, Marine, Zhang, Tian, Burke, John M., Doshi, Gurjyot, Melichar, Bohuslav, Kopyltsov, Evgeniy, Alva, Ajjai, Oudard, Stephane, Topart, Delphine, Hammers, Hans, Kitamura, Hiroshi, McDermott, David F., Silva, Adriano, Winquist, Eric, Cornell, Jerry, Elfiky, Aymen, Burgents, Joseph E., Perini, Rodolfo F., Powles, Thomas

Volltext

Transforming the Perioperative Treatment Paradigm in Non-Metastatic RCC—A Possible Path Forward von Harshman, L.C., Drake, C.G., Haas, N.B., Manola, J., Puligandla, M., Signoretti, S., Cella, D., Gupta, R.T., Bhatt, R., Van Allen, E., Lara, P., Choueiri, T.K., Kapoor, A., Heng, D.Y.C., Shuch, B., Jewett, M., George, D., Michaelson, D., Carducci, M.A., McDermott, D., Allaf, M.

Volltext

Phase I/pharmacokinetic study of topotecan by 24-hour continuous infusion weekly von HAAS, N. B, LACRETA, F. P, WALCZAK, J, HUDES, G. R, BRENNAN, J. M, OZOLS, R. F, O'DWYER, P. J

Volltext

DNA-binding specificity of the PAR basic leucine zipper protein VBP partially overlaps those of the C/EBP and CREB/ATF families and is influenced by domains that flank the core bas... von Haas, Naomi B., Cantwell, Carrie A., Johnson, Peter F., Burch, John B. E.

Volltext

158PPlasma KIM-1 is associated with clinical outcomes after resection for localized renal cell carcinoma: A trial of the ECOG-ACRIN Research Group (E2805) von Xu, W, Puligandla, M, Haas, N B, Flaherty, K T, Uzzo, R G, Sabbisetti, V, Dutcher, J J, DiPaola, R S, Bhatt, R S

Volltext

1186PDSafety and efficacy of the oral CXCR4 inhibitor X4P-001 + axitinib in advanced renal cell carcinoma patients: An analysis of subgroup responses by prior treatment von McDermott, D F, Vaishampayan, U, Matrana, M, Rha, S Y, Saavedra, A Zurita, Ho, T, Keam, B, Lee, J-L, Joseph, R, Ali, S, Stadler, W, Haas, N B, Sundararajan, S, Park, S H, Mowat, R, Picus, J, Dudek, A Z, Zakharia, Y, Gan, L, Atkins, M B

Volltext

Chicken repeat 1 (CR1) elements, which define an ancient family of vertebrate non-LTR retrotransposons, contain two closely spaced open reading frames von Haas, Naomi B, Grabowski, Joann M, Sivitz, Adam B, Burch, John B.E

Volltext

Clinical, pharmacokinetic and biological studies of topotecan von O'DWYER, P. J, LACRETA, F. P, HAAS, N. B, HALBHERR, T, FRUCHT, H, GOOSENBERG, E, KANG-SHEN YAO

Volltext

Vinblastine and estramustine phosphate in metastatic renal cell carcinoma: A phase II trial of the Fox Chase Network von HAAS, Naomi B, GIANTONIO, Bruce J, HUDES, Gary R, LITWIN, Samuel, MINNITI, Carl J, FOX, Stephen, YESLOW, Gwen, REILLY, Robert, NAHUM, Kenneth, GREENBERG, Richard, HALBHERR, Theresa

Volltext

Phase I trial of 5-fluorouracil by 24-hour infusion weekly von HAAS, N. B, HINES, J. B, HUDES, G. R, JOHNSTON, N, OZOLS, R. F, O'DWYER, P. J

Volltext

Validation of a new prognostic model to easily predict outcome in renal cell carcinoma: the GRANT score applied to the ASSURE trial population von Buti, S, Puligandla, M, Bersanelli, M, DiPaola, R S, Manola, J, Taguchi, S, Haas, N B

Volltext